Among patients with extensively drug-resistant (XDR) tuberculosis, adding linezolid (Zyvox) to standard therapies appears to improve treatment response, but with a high rate of adverse events, a phase IIb trial showed.

The investigational drug delamanid may help combat multidrug-resistant tuberculosis, results of a phase II trial indicate.